Economic evaluation of prostate cancer screening: a systematic review (Q38352868)

2 September 2017

0 references

1 reference

title

Economic evaluation of prostate cancer screening: a systematic review (English)

1 reference

prostate cancer screening

2 September 2017

main subject

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25675126 AND SRC:MED&resulttype=core&format=json

2 June 2020

2

Charis Brown

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25675126 AND SRC:MED&resulttype=core&format=json

2 June 2020

4

Richard Edlin

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25675126 AND SRC:MED&resulttype=core&format=json

2 June 2020

5

Ross Lawrenson

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25675126 AND SRC:MED&resulttype=core&format=json

2 June 2020

author name string

Paul Rouse

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25675126 AND SRC:MED&resulttype=core&format=json

2 June 2020

language of work or name

English

0 references

publication date

1 January 2015

1 reference

2 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25675126 AND SRC:MED&resulttype=core&format=json

2 June 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25675126 AND SRC:MED&resulttype=core&format=json

2 June 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25675126 AND SRC:MED&resulttype=core&format=json

2 June 2020

page(s)

467-477

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25675126 AND SRC:MED&resulttype=core&format=json

2 June 2020

cites work

Global cancer statistics

1 reference

Early detection of prostate cancer: AUA Guideline

21 January 2018

1 reference

Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons

21 January 2018

1 reference

Prostate-cancer mortality at 11 years of follow-up

21 January 2018

1 reference

Mortality results from the Göteborg randomised population-based prostate-cancer screening trial

21 January 2018

1 reference

Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up

21 January 2018

1 reference

Screening for prostate cancer: an updated Cochrane systematic review

21 January 2018

1 reference

Economic evaluation and decision making in the UK.

21 January 2018

1 reference

Screening for carcinoma of the prostate by digital rectal examination in a randomly selected population

21 January 2018

1 reference

Screening for prostate cancer. A decision analytic view

21 January 2018

1 reference

Cost-effectiveness analysis in early detection of prostate cancer: an evaluation of six screening strategies in a randomly selected population of 2,400 men.

21 January 2018

1 reference

Economic evaluation of screening for prostate cancer: a randomized population based programme during a 10-year period in Sweden

21 January 2018

1 reference

Cost-effectiveness analysis of prostate cancer screening

21 January 2018

1 reference

A quantitative analysis of the costs and benefits of prostate cancer screening

21 January 2018

1 reference

Cost-benefit analysis of total, free/total, and complexed prostate-specific antigen for prostate cancer screening

21 January 2018

1 reference

Costs and effects of prostate cancer screening in Sweden--a 15-year follow-up of a randomized trial

21 January 2018

1 reference

Prostate cancer screening strategies with re-screening interval determined by individual baseline prostate-specific antigen values are cost-effective

21 January 2018

1 reference

Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer

21 January 2018

1 reference

Cost-Effectiveness of Prostate Specific Antigen Screening in the United States: Extrapolating From the European Study of Screening for Prostate Cancer

21 January 2018

1 reference

Risk assessment to guide prostate cancer screening decisions: a cost-effectiveness analysis

21 January 2018

1 reference

Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada

21 January 2018

1 reference

Using threshold values for cost per quality-adjusted life-year gained in healthcare decisions

21 January 2018

1 reference

Economic evaluation of prostate cancer screening with prostate-specific antigen.

21 January 2018

1 reference

Response: Reading between the lines of cancer screening trials: using modeling to understand the evidence

21 January 2018

1 reference

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

21 January 2018

1 reference

Anxiety and depression after prostate cancer diagnosis and treatment: 5-year follow-up.

21 January 2018

1 reference

Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold.

21 January 2018

1 reference

The costs of identifying undiagnosed prostate cancer in asymptomatic men in New Zealand general practice

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FON.14.273

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25675126 AND SRC:MED&resulttype=core&format=json

2 June 2020

1 reference